Mark L Oldham

US Patent:

7532705, May 12, 2009

Filed:

Apr 10, 2007

Appl. No.:

11/786075

Inventors:

Fang-Fang Yin - Chapel Hill NC, US
Devon J. Godfrey - Hillsborough NC, US
Mark Oldham - Durham NC, US

Assignee:

Duke University - Durham NC

International Classification:

A61N 5/10

US Classification:

378 65, 378 22, 382294

Abstract:

Systems and methods for localizing a target for radiotherapy based on digital tomosynthesis are provided. According to one method, DTS verification image data of a target located within or on a patient is generated. The DTS verification image data is compared with DTS reference image data of the target. Radiotherapy positioning information is determined based on the comparison of the DTS verification and reference image data.

US Patent:

20200282056, Sep 10, 2020

Filed:

Feb 2, 2017

Appl. No.:

16/074707

Inventors:

- Detroit MI, US
- Durham NC, US
Zakaryae FATHI - Raleigh NC, US
Wayne BEYER - Bahama NC, US
Mark OLDHAM - Durham NC, US
Justus ADAMSON - Durham NC, US
Michael NOLAN - Raleigh NC, US

Assignee:

IMMUNOLIGHT, LLC - Detroit MI
DUKE UNIVERSITY - Durham NC

International Classification:

A61K 41/00
A61K 31/37
A61N 5/06
A61N 5/10

Abstract:

A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

US Patent:

20200222711, Jul 16, 2020

Filed:

Dec 27, 2019

Appl. No.:

16/728803

Inventors:

- Detroit MI, US
- Durham NC, US
Zakaryae Fathi - Raleigh NC, US
Mark Dewhirst - Durham NC, US
Mark Oldham - Durham NC, US
Justus Adamson - Durham NC, US
Michael Nolan - Raleigh NC, US

Assignee:

IMMUNOLIGHT, LLC. - Detroit MI
DUKE UNIVERSITY - Durham NC

International Classification:

A61N 5/06
A61K 41/17
A61K 39/00
A61K 41/00
A61K 49/04
A61N 5/02
A61N 5/10

Abstract:

A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

US Patent:

20190184190, Jun 20, 2019

Filed:

Aug 1, 2017

Appl. No.:

16/322178

Inventors:

- Detroit MI, US
- Durham NC, US
Zakaryae FATHI - Raleigh NC, US
Wayne BEYER - Bahama NC, US
Mark OLDHAM - Durham NC, US
Justus ADAMSON - Durham NC, US
Paul YOON - Durham NC, US

Assignee:

IMMUNOLIGHT, LLC - Detroit MI
DUKE UNIVERSITY - Durham NC

International Classification:

A61N 5/06
A61N 5/10
A61P 35/00
A61K 41/00

Abstract:

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

US Patent:

20180344850, Dec 6, 2018

Filed:

May 30, 2018

Appl. No.:

15/992852

Inventors:

- Detroit MI, US
- Durham NC, US
Neil SPECTOR - Durham NC, US
Paul YOON - Durham NC, US
Justus ADAMSON - Durham NC, US
David ALCORTA - Durham NC, US
Kim LYERLY - Durham NC, US
Leihua LIU - Durham NC, US
Takuya OSADA - Durham NC, US
Mark OLDHAM - Durham NC, US
Zakaryae FATHI - Raleigh NC, US
Wayne F. BEYER - Bahama NC, US
Harold WALDER - Belville NC, US

Assignee:

IMMUNOLIGHT, LLC - Detroit MI
DUKE UNIVERSITY - Durham NC

International Classification:

A61K 41/00
A61K 31/37
A61K 45/06
A61K 9/00

Abstract:

A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

Author:

Mark Oldham

ISBN #:

0340415738